FDA Clears Opus Genetics’ Eye Drop for Presbyopia
The approval expands RYZUMVI’s use to adults with presbyopia and triggers a milestone payment to Opus Genetics.
Makkler Newsroom · Oct 16, 07:24 PM · 1 min read
Market closed· · AUD · Data may be delayed
Not enough data
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO